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Sumoylation of the papillomavirus (PV) origin binding helicase E1 protein is critical for its function. Consequently, factors modulating
the sumoylation of E1 could ultimately alter the outcome of a papillomavirus infection. We investigated the role played by phosphorylation
and two known SUMO E3 ligases, RanBP2 and PIAS proteins, on the sumoylation of E1. E1 sumoylation was unaffected by
phosphorylation as both wild-type and pseudo-phosphorylation mutants of BPV E1 exhibited similar sumoylation profiles. RanBP2 bound to
BPV E1, but not to HPV11 E1, and lacked sumoylation enhancing activity for either E1. In contrast, proteins of the PIAS family (except
PIASy) bound to both BPVand HPV11 E1 and stimulated their sumoylation. The structural integrity of the RING finger domain of the PIAS
proteins was required for their E3 SUMO ligase activity on PV E1 sumoylation but was dispensable for their PV E1 binding activity. Miz1,
the PIAS protein exerting the strongest E1 sumoylation enhancing activity, favored SUMO1 versus SUMO2 as the modifier and was shown
to be transcribed in a keratinocyte cell line. This study indicates PIAS proteins as possible modulators of PV E1 sumoylation during
papillomavirus infections.
D 2004 Elsevier Inc. All rights reserved.
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Papillomaviruses (PVs) are the etiological agents of
warts in humans and animals, are the primary risk factor
associated with cervical cancer, and are associated with
anogenital cancers and other pathologies (Zur Hausen,
1996). PVs replicate their small genomes (approximately
8000 bp) episomally in the nucleus of the infected cell.
This ability is conferred by the E1 protein, a viral-encoded
protein that recognizes the viral origin of replication (in
conjunction with the E2 viral protein), recruits host cell
replication proteins to the origin, and initiates DNA
replication via its helicase activity (reviewed in Wilson et
al., 2002). Thus, the E1 and the E2 proteins are the only0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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of viral DNA, with the rest of the replication machinery
being provided by the host (Melendy et al., 1995).
Comparison between the predicted human papillomavirus
(HPV) E1s and the well-characterized bovine papilloma-
virus type 1 (BPV) E1 reveals common physical features,
such as acidic isoelectric point, similar molecular weight,
and a tripartite organization consisting of an N-terminal
region of undefined activity, a variable-length spacer, and a
larger C-terminal region with DNA binding, ATPase, and
helicase activities (Wilson et al., 2002). In concert with
their related physical properties, BPV and HPV E1s are
similarly phosphorylated at multiple serine and threonine
residues by several kinases, including cyclin E-cdc2 kinase
(Cueille et al., 1998; Lentz et al., 1993; Ma et al., 1999),
protein kinases A and C (Zanardi et al., 1997), and casein
kinase II (Lentz, 2002; McShan and Wilson, 1997). In
addition to phosphorylation, E1 proteins are also post-
translationally modified by a process known as sumoyla-05) 190–203
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2000).
Sumoylation consists of the covalent attachment of a
small ubiquitin-related protein moiety (SUMO) to a substrate
protein via an isopeptide bond formed between the carboxyl
group of the C terminal glycine in SUMO and the epsilon
amino group of a lysine residue in the substrate protein
(reviewed in Kim et al., 2002). Sumoylation involves four
enzymatic steps: (1) proteolytic cleavage of SUMO to
expose the internal diglycine motif required for conjugation,
(2) ATP-dependent activation of SUMO by the heterodi-
meric SUMO activating enzyme SAE1/SAE2, (3) transfer of
SUMO to the conjugating enzyme Ubc9, and (4) conjugation
of SUMO to the target substrate protein. Sumoylation can be
recapitulated in vitro by incubating the substrate with a
mixture of purified SAE1/SAE2, Ubc9, and a C-terminal
truncated SUMO protein (ending in-GG), in the presence of
ATP (Desterro et al., 1999; Okuma et al., 1999). During the
past 2 years, several groups have presented evidence that
although no other enzymatic activity is required for
sumoylation in vitro, there are proteins that enhance the
sumoylation of specific substrates both in vitro and in vivo
(Johnson and Gupta, 2001; Kagey et al., 2003; Kahyo et al.,
2001; Kirsh et al., 2002; Kotaja et al., 2002; Pichler et al.,
2002; Sachdev et al., 2001; Schmidt and Muller, 2002). This
enhancing effect resembles the one mediated by the E3
ligases in the ubiquitination pathway; thus, these sumoyla-
tion enhancers have been dubbed as E3 SUMO ligases
(Pichler et al., 2002). At present, three types of SUMO E3
ligases have been described: RanBP2, proteins belonging to
the PIAS family, and the polycomb protein, Pc2.
RanBP2 (also known as Nup358) is the largest structural
component of the nuclear pore complex, where it is localized
to the cytosolic extensions or fibrils of the nuclear pore (Wu
et al., 1995). RanBP2 contains two Zinc fingers, four
RanGTP binding domains, a domain containing two internal
repeat motifs, and a series of loosely spaced FG repeats
thought to play a relevant role in nuclear traffic by providing
docking sites for nuclear traffic factors (transportins)
(Azuma and Dasso, 2002). The domain containing the two
internal repeat motifs provides RanBP2 with the ability to
bind to Ubc9 and SUMO1 and to become sumoylated
(Matunis et al., 1998). A smaller version of this region,
lacking the FG repeat (referred to as RanBP2DFG), has been
shown to enhance its own sumoylation and stimulate the
sumoylation of Sp100 (Pichler et al., 2002), HDAC4 (Kirsh
et al., 2002), and Mdm2 (Miyauchi et al., 2002).
PIAS1, the prototypical member of the PIAS family, was
initially characterized by its ability to inhibit STAT-mediated
signaling pathways (hence its name, protein inhibitor of
activated STAT) (Liu et al., 1998), but its ability to interact
with p53 (Gallagher et al., 1999) and SUMO1 (Kahyo et al.,
2001) led to the prediction that PIAS1 could act as a SUMO
E3 ligase for p53; this was tested and confirmed by Kahyo
et al. (2001). Simultaneously, Johnson and Gupta (2001)
described that the yeast PIAS homologues, Siz1 and Siz2,promote sumoylation of the septins (the major sumoylation
target in yeast), thus characterizing PIAS proteins as SUMO
E3 ligases. PIAS proteins are characterized by the presence
of an N-terminal SAP (SAF-A/B, Acinus, PIAS) domain, a
central RING finger domain where two consensus cysteine
residues for a Zinc finger domain have been replaced by
serine and aspartic acid, and a C-terminal acidic domain.
The SAP domain in PIASy mediates its binding to LEF1
(Sachdev et al., 2001) and may play a role in the interaction
with other sumoylation substrates (Jackson, 2001). The
RING finger domain has been determined to be structurally
required for the SUMO E3 ligase of the PIAS proteins, as
mutations disrupting its integrity preclude the sumoylation
enhancing activity mediated by PIAS proteins (Kahyo et al.,
2001; Kotaja et al., 2002; Nakagawa and Yokosawa, 2002;
Nishida and Yasuda, 2002; Schmidt and Muller, 2002).
However, such mutations exert little or no effect on the
ability of PIAS proteins to interact with the sumoylation
substrates for which this has been tested (Kahyo et al.,
2001). The current list of substrates for the SUMO E3 ligase
activity of the members of the PIAS family includes p53
(Kahyo et al., 2001; Schmidt and Muller, 2002), GRIP1
(Kotaja et al., 2002), AR (Kotaja et al., 2002; Nishida and
Yasuda, 2002), LEF1 (Sachdev et al., 2001), c-Jun (Kotaja
et al., 2002; Schmidt and Muller, 2002), c-Myb (Dahle et
al., 2003), Mdm2 (Miyauchi et al., 2002), IRF-1 (Nakagawa
and Yokosawa, 2002), C/EBPalpha (Subramanian et al.,
2003), Sp3 (Sapetschnig et al., 2002), PLAG1 (Van Dyck et
al., 2004), PPAR (Ohshima et al., 2004), Smad4 (Lee et al.,
2003; Ohshima and Shimotohno, 2003), Smad3 (Imoto et
al., 2003), MR (Tallec et al., 2003), STAT1 (Rogers et al.,
2003; Ungureanu et al., 2003), Axin (Rui et al., 2002), and
the yeast septins (Johnson and Gupta, 2001).
The PC2 protein belongs to the polycomb group (PcG) of
nuclear proteins, which were initially identified as regulators
of homeotic gene expression in Drosophila. The PcG
mammalian homologues appear to form nuclear complexes
(known as PcG bodies) that bind DNA and exert a repressive
effect on gene expression over long distances in the
chromosomes. Pc2 was identified as an interacting factor
for the transcriptional corepressor carboxyl-terminus binding
protein (CtBP) and was shown to enhance its sumoylation
probably by recruiting CtBP and Ubc9 to PcG bodies (Kagey
et al., 2003). To date, no other substrates for the SUMO E3
ligase activity of Pc2 have been described.
In addition to the sumoylation enhancing effect mediated
by the E3 SUMO ligases, the sumoylation of some SUMO
substrates is affected by phosphorylation, although the type
of effect appears to be protein specific. For instance,
phosphorylation of HSF1 enhances its sumoylation (Hieta-
kangas et al., 2003; Hilgarth et al., 2003), whereas
phosphorylation of the human cytomegalovirus (HCMV)
immediate–early protein IE1/IE72 decreases its sumoylation
(Spengler et al., 2002).
Our previous studies with PV E1 demonstrated that
mutations impairing BPV E1 sumoylation disrupt proper
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replication defect (Rangasamy et al., 2000). Thus, factors
modulating E1 sumoylation may ultimately regulate and
alter the outcome of a BPV infection and more generally of
any PV infection as other papillomavirus E1 proteins are
also sumoylated (Rangasamy et al., 2000). Consequently,
we now sought to identify the factors that modulate the
sumoylation of E1. We found that pseudo-phosphorylation
of BPV E1 had no significant effect on its sumoylation. In
contrast, out of all the E3 SUMO ligases tested, all of the
PIAS family proteins (except PIASy) were able to specif-
ically interact with both BPV E1 and HPV11 E1 and
enhance their sumoylation, with PIASxh (Miz1) producing
the largest sumoylation enhancing effect. Such enhancing
activity was dependant upon the integrity of the RING
finger domain, although the disruption of this domain had
no effect on the PV E1 binding activity of the PIAS
proteins. RanBP2 exhibited significant binding activity only
toward BPV E1 but failed to enhance its sumoylation. The
enhancing effect mediated by the PIAS proteins on BPV E1
was more pronounced than on HPV11 E1, thus suggesting
slight differences in the way the sumoylation of these
proteins is regulated. Furthermore, the enhancing effect of
PIASxh on PV E1 sumoylation was greatly reduced when
SUMO2 was used as the modifier, thus indicating that the
E3 SUMO ligase activity exerted by PIAS proteins on PV
E1 favors their SUMO1 modification. Altogether, this study
supports PIAS proteins as possible modulators of PV E1
sumoylation during papillomavirus infections.Fig. 1. The in vitro sumoylation of BPV E1 is not altered by the
introduction of pseudo-phosphorylation mutations. Two microliters of 35S-
labeled in vitro translated wild-type BPV E1 protein or pseudo-phosphor-
ylation mutant E1 proteins was incubated with (+) or without () 1 Ag of
SAE1/SAE2, 1.5 Ag of SUMO1, and 300 ng of Ubc9. After incubation, the
samples were resolved on a 7.5% SDS-PAGE gel and analyzed by
phosphordensitometry. The pseudo-phosphorylation mutations introduced
corresponded to Asp substitutions of the residues indicated for each mutant:
CDK (cell-cycle-dependent kinase sites mutant), T102, T126, and S283;
CKII (Casein kinase II sites mutant), S48 and S584; ALL (all known
phosphorylation sites mutant), S48, T102, S109, T126, S283, and S584.Results
Pseudo-phosphorylation mutations do not affect BPV E1
sumoylation
Papillomavirus E1 proteins are phosphorylated at several
amino acid residues by the action of different host cellular
kinases. To test if phosphorylation of E1 altered its
sumoylation, we used site-directed mutagenesis of an in
vitro translation plasmid coding for BPV E1 to develop a
series of BPV E1 pseudo-phosphorylation mutants contain-
ing Asp as a substitute for known phosphorylated Ser and/or
Thr residues. The effect of these pseudo-phosphorylations
on E1 sumoylation was tested in an in vitro sumoylation
assay using purified Escherichia coli-expressed sumoyla-
tion enzymes as previously reported (Tatham et al., 2001).
The in vitro sumoylation reactions were resolved in SDS-
PAGE gels, transferred to Immobilon membranes, and
analyzed by autoradiography and phosphordensitometry.
To verify the activity of the purified sumoylation enzymes,
we performed in vitro sumoylation of a purified protein
corresponding to a subregion of RanBP2, known as RanBP2
FG, as this subregion stimulates its own sumoylation and is
efficiently sumoylated in vitro (Pichler et al., 2002). These
preliminary tests indicated that our purified sumoylationcomponents were highly active (data not shown). Compared
to WT unphosphorylated E1, there was no observable effect
on E1 sumoylation with any of the single substitution
mutants tested (residues S48, T102, S109, T126, S283, or
S584), indicating that phosphorylation of these individual
amino acid residues is unlikely to be involved in regulating
E1 sumoylation (data not shown). However, it was possible
that more than one phosphorylation event was required to
alter sumoylation. Therefore, three additional mutants were
developed in which all the casein kinase 2 sites (CKII
mutant), cell-cycle-dependent kinase sites (CDK mutant), or
all known phosphorylated residues (ALL mutant) were
simultaneously substituted by aspartic acid. When tested in
four independent in vitro sumoylation experiments, these
pseudo-phosphorylated mutants did not show significant
differences in the profile of sumoylated products as
compared with unphosphorylated WT E1 (Fig. 1, compare
lanes 4, 6, and 8 with lane 2). Thus, we were unable to
demonstrate any effect of pseudo-phosphorylation on E1
sumoylation in vitro, suggesting that phosphorylation is
unlikely to regulate the sumoylation of E1 in vivo.
PIAS proteins interact with both BPV E1 and HPV11 E1
Recently, proteins exhibiting features of an E3 ligase for
sumoylation have been characterized (Kagey et al., 2003;
Pichler et al., 2002; Schmidt and Muller, 2002). Although
their mechanism of action has not been clearly delineated, it
is conceivable that these SUMO ligases may establish a
direct interaction with substrate proteins to enhance their
sumoylation. We sought to investigate if either of two well-
characterized classes of SUMO ligases, PIAS proteins and
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papillomavirus E1 proteins. First, the ability of bovine
papillomavirus E1 (BPV E1) to interact with either of these
two E3 SUMO ligases in vitro was examined. In vitro
translated, radiolabeled BPV E1 was incubated with purified
GST-PIAS1 and their interaction assessed by a pulldown
assay. Since the SUMO conjugase, Ubc9, could potentially
stabilize the interaction between BPV E1 and the SUMO
ligases, we also performed pulldown experiments supple-
mented with purified recombinant Ubc9. BPV E1 did not
bind to GST alone (Fig. 2, lanes 2–5), but bound to GST-
PIAS1 in a protein concentration-dependent manner (Fig. 2,
lanes 6–8); such binding did not seem to be enhanced or
compromised by Ubc9, as judged by the intensity of the BPV
E1 signals obtained (Fig. 2, compare lanes 8 and 9). Similar
pulldown experiments were performed to determine if
RanBP2 interacted with BPV E1, using in vitro translated
BPV E1 and a GST fusion protein corresponding to the
region in RanBP2 reported to contain the necessary
determinants for SUMO modification and E3 ligase activity
(GST-RanBP2DFG; Pichler et al., 2002). As for PIAS1, BPV
E1 bound to GST-RanBP2DFG in a protein concentration-
dependent manner (Fig. 2, lanes 10–12), and Ubc9 did not
alter the binding of BPV E1 to GST-RanBP2DFG (Fig. 2,
compare lanes 12 and 13). An unrelated in vitro translated
control protein (luciferase) did not bind to GST-PIAS1 or to
GST-RanBP2DFG (Fig. 2, lanes 15–25), thus indicating that
the E1 binding was not due to an intrinsic nonspecific
binding by the GST fusion proteins tested.
In mammals, the PIAS family comprises five different
PIAS proteins, namely PIAS1, the two alternative splicing
forms of PIASxa (PIASxa/ARIP3 and PIASxh/Miz1),
PIASy, and PIAS3. The binding of BPV E1 to PIAS1
suggested the possibility that BPV E1 could interact with
other members of the PIAS family as well. To test this
possibility, GST fusions of other members of the PIAS
family were affinity purified and tested for E1 binding by
pulldown experiments as for PIAS1. The purified GST
fusion proteins used for this and all subsequent experimentsFig. 2. BPV E1 interacts with GST-PIAS1 and GST-RanBP2DFG. Two, 6, or 12
glutathione-sepharose 4B beads and 3 Al of 35S-labeled in vitro translated BPV E1
analyzed by autoradiography. The lane marked i (input) represents 50% of the in
samples were supplemented with 10 Ag of Ubc9. Numbers to the left indicate mwere evaluated by SDS-PAGE followed by Coomassie blue
or immunoblotting using anti-GST antibodies. Notably, all
the purified GST-PIAS proteins displayed complex patterns
of protein bands when resolved by SDS-PAGE, indicating
that they were obtained largely as mixtures of full-length
and truncated forms (data not shown). However, the
distribution between full-length and truncated forms was
similar for all the PIAS proteins, so they should be directly
comparable in the E1 binding assay. In contrast, GST-
RanBP2DFG appeared predominantly as a single band of
the expected molecular weight, with only a minor compo-
nent of truncated forms.
With the exception of PIASy, all of the tested members of
the PIAS family bound to BPV E1, including a mutant GST-
ARIP3 (GST-ARIP3[W383A]) protein containing a single
Trp to Ala replacement located in the middle of the RING
finger domain (Figs. 3A and B). Since the above mutation is
known to disrupt the structure of the RING finger domain
(Kotaja et al., 2002), this indicates that the RING finger
domain is not essential for the binding of BPV E1 to GST-
ARIP3. Binding of BPV E1 to GST-RanBP2DFG was
comparable to that observed for the PIAS proteins (except
for PIASy).
To evaluate which region(s) of E1 mediates the
interaction with PIAS proteins, a small series of previously
described E1 truncations (Leng et al., 1997) was tested in
the pulldown assay against PIAS1 and Miz1. However, no
clearly defined interaction domain could be determined with
the available truncation set (data not shown). In general, E1
constructs containing the central region of E1 (residues
121–458) exhibited PIAS binding, though for some nested
truncations smaller E1 fragments showed PIAS interaction
while a more inclusive larger fragment failed to bind,
possibly reflecting conformational issues with the truncated
E1 proteins. Additionally, in some cases discrete, non-
overlapping E1 regions each interacted with PIAS. Whether
this reflects multiple, authentic interactions between differ-
ent regions of E1 and the PIAS proteins or spurious
interactions with conformationally abnormal E1 truncationsAg of either GST-PIAS1 or GST-RanBP2DFG was incubated with 20 Al of
or Luciferase. Bound proteins were resolved on an 8% SDS-PAGE gel and
vitro translation protein mixture used in the binding reaction. Underlined
olecular weight markers (in kDa).
Fig. 3. Interactions between PV E1 proteins and known SUMO-E3 ligases. Twelve micrograms of each purified GST fusion protein was incubated with 20 Al of
glutathione-sepharose 4B beads and 3 Al of 35S-labeled in vitro translated BPV E1 or HPV11 E1. Bound proteins were resolved on a 10% SDS-PAGE gel and
analyzed by phosphordensitometry. Panels A and C show autoradiographs obtained in representative experiments using BPV E1 and HPV11 E1, respectively.
Panels B and D show quantitative data obtained in two or three experiments performed with BPV E1 and HPV11 E1, respectively. The binding of the PV E1
proteins to the different GST fusion proteins is represented as percentage of the initial material (% input). Error bars presented in this and subsequent figures
represent standard error. Panel E shows a schematic representation of the primary structure of the PIAS family protein members used in this study. Numbers
indicate the amino acid residues limiting the different domains identified within the primary structure of the PIAS proteins. SAP stands for the SAF-A/B,
Acinus, PIAS domain. Length differences observed among the PIAS proteins are all due to variations in the C-terminal ends of the proteins.
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PIAS interaction site(s) on E1 was not possible with these
truncations. A more thorough point mutational analysis will
be required to establish critical E1 sequences and regions for
PIAS binding.
Our previous study indicated that, in addition to BPV E1,
the E1 proteins from one cutaneous and one mucosal human
PV were also sumoylated, consistent with a general role for
sumoylation in PV E1 function (Rangasamy et al., 2000). To
determine if E3 SUMO ligases could also bind to the E1
protein from a human papillomavirus, we performed similar
pulldown experiments using in vitro translated E1 from
human papillomavirus 11 (HPV11 E1). Consistent with theBPV E1 results, all of the members of the PIAS family
tested bound to HPV11 E1, with the exception of PIASy;
however, unlike BPV E1, HPV11 E1 did not bind to GST-
RanBP2DFG (Figs. 3C and D).
PIAS 1 enhances the in vitro sumoylation of PV E1
The ability of BPV E1 to establish protein interactions
with the two previously characterized E3-SUMO ligases,
RanBP2DFG and PIAS proteins, suggested that these
proteins could potentially act as E3 ligases for BPV E1
sumoylation. To test this hypothesis, we performed in vitro
sumoylation assays of in vitro translated BPV E1 with and
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(Rangasamy and Wilson, 2000; Rangasamy et al., 2000),
incubation of BPV E1 with a full set of sumoylation
components resulted in the appearance of high molecular
weight forms of E1 (Fig. 4A). The molecular weights of
the novel forms of E1 were consistent with the addition of
one, two, or several SUMO molecules to E1. The
abundance of the high molecular weight forms increased
with the addition to the reaction mixture of increasing
amounts of GST-PIAS1 (Fig. 4A, lanes 2–5). Phosphor-
densitometric quantification of the predominant sumoy-
lated form of BPV E1 indicated that GST-PIAS1 reached a
maximum stimulatory effect of two- to threefold on BPV
E1 sumoylation at 5 Ag per reaction, and that such
stimulatory effect decreased slightly at higher concentra-
tions (Fig. 4C). In contrast, the addition of GST-Ran-
BP2DFG at concentrations slightly lower than those used
for GST-PIAS1 seemed to exert an inhibitory effect on
BPV E1 sumoylation, leading to a decrease in the amount
of BPV E1 sumoylated products that became more
prominent as the amount of GST-RanBP2DFG increased
(Figs. 4A and C). This apparent inhibitory activity of GST-
RanBP2DFG on BPV E1 sumoylation prevailed over the
stimulatory activity mediated by GST-PIAS1 when the twoFig. 4. The in vitro sumoylation of PV E1 is enhanced by GST-PIAS1 but not by G
or HPV11 E1 was incubated with (+) or without () 1 Ag of SAE1/SAE2, 1.5 Ag
PIAS1 or GST-RanBP2DFG. After incubation, the samples were resolved on an 8
show autoradiographs of the sumoylation profiles obtained for BPV E1 and HPV11
kDa). Panels C and D are graphic representations (in arbitrary units) of the data
product obtained for BPV E1 and HPV11 E1, respectively.E3 ligases were combined in the same in vitro sumoylation
reaction (Fig. 4A, lane 11).
To determine if GST-PIAS1 and GST-RanBP2DFG
enhanced sumoylation of other PV E1 proteins, we per-
formed similar in vitro sumoylation assays using HPV11
E1. As observed for BPV E1, the addition of GST-PIAS1
stimulated HPV11 E1 sumoylation with increasing amounts
of GST-PIAS1 leading to larger amounts of the sumoylated
products (Fig. 4B, lanes 2–6). However, while the stim-
ulatory effect continued to increase up to a concentration of
25 Ag of GST-PIAS1 per reaction, it did not appear to be as
dramatic as the one observed for BPV E1 sumoylation
(compare Figs. 4C and D). GST-RanBP2DFG failed to
stimulate sumoylation of 11E1 and instead exerted an
inhibitory effect on 11E1 sumoylation (Figs. 4B and D)
which prevailed over the stimulatory activity of GST-PIAS1
(Fig. 4B, lane 11), as previously seen for BPV E1.
Immunoblotting analyses using anti-GST antibodies indi-
cated that in vitro E1 sumoylation reactions performed with
the GST-RanBP2DFG E3 ligase resulted in large amounts of
sumoylated GST-RanBP2DFG, suggesting that the apparent
inhibitory effect of GST-RanBP2DFG on E1 sumoylation
was due to competition for free SUMO1 (data not shown).
As very small amounts of RanBP2DFG suffice for the E3ST-RanBP2DFG. Two microliters of 35S-labeled in vitro translated BPV E1
of SUMO1, 280 ng of Ubc9, and the indicated amounts of purified GST-
% SDS-PAGE gel and analyzed by phosphordensitometry. Panels A and B
E1, respectively. Numbers to the left indicate molecular weight markers (in
obtained by phosphordensitometry measurement of the major sumoylated
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range of 1–5 ng per reaction) and larger amounts of
RanBP2DFG are inhibitory for the sumoylation of Sp100
(Pichler et al., 2002), we performed additional in vitro
sumoylation assays of BPV E1 using smaller amounts of
GST-RanBP2DFG (1–20 ng per reaction; for example, see
Figs. 5A and B). Under these conditions, GST-RanBP2DFG
still lacked a stimulatory effect on BPV E1 sumoylation,
although it was able to stimulate the sumoylation of Sp100
(data not shown). However, the inhibitory effect on E1
sumoylation observed at higher concentrations of GST-
RanBP2DFG was now absent, consistent with a competitiveFig. 5. Miz1 (PIASxh) is the PIAS family member protein that exerts the highest s
vitro translated BPV E1 or HPV11 E1 were incubated with buffer only (lanes ma
plus Sae2/1 plus Ubc9 (lanes marked bALLQ). Where indicated, reactions were su
Miz1; each at 2 Ag), or RanBP2DFG (20 ng). The amounts used per reaction of th
1.5 Ag of SUMO1. After incubation, the samples were resolved on 8% or 10% SD
autoradiographs of the representative sumoylation profile obtained for BPV E1
proteins. The unmodified E1 (arrow) and the sumoylated products (S-E1, bracket)
of the major sumoylated product obtained for BPV E1 and HPV11 E1, respect
percentage sumoylation activity as determined by assigning 100% sumoylation
components (SAE1/SAE2+Ubc9+SUMO1).inhibition mechanism. Thus, over a wide range of concen-
trations and conditions, while GST-RanBP2DFG exhibited
E3 ligase activity towards itself and/or Sp100, there was no
detectable stimulation of E1 sumoylation, consistent with
RanBP2 lacking SUMO ligase ability for E1 proteins.
Miz1 (PIASxb) is the PIAS family member protein that
exerts the highest stimulatory activity on PV E1 sumoylation
To evaluate if the individual members of the PIAS family
differed in their ability to stimulate the sumoylation of BPV
E1, we performed additional sets of in vitro sumoylationtimulatory activity on PV E1 sumoylation. Two microliters of 35S-labeled in
rked bNoneQ), SUMO1 plus Ubc9 (lanes marked bNo Sae2/1Q), or SUMO1
pplemented with GST (2 Ag), PIAS proteins (ARIP3, ARIP3[W383A], or
e sumoylation components were 1 Ag of SAE1/SAE2, 280 ng of Ubc9, and
S-PAGE gels and analyzed by phosphordensitometry. Panels A and B show
and HPV11 E1, respectively, in the presence of the different GST fusion
are indicated. Panels C and D show the phosphordensitometry quantification
ively, averaged from two or three experiments. The data are expressed as
activity to the reaction performed in the presence of all the sumoylation
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proteins at the concentration estimated to be optimal for GST-
PIAS1. GST-RanBP2DFG was also evaluated in these
assays, at a concentration of 20 ng per reaction. Differences
among the members of the PIAS family were observed in
their ability to stimulate BPV E1 sumoylation (Figs. 5A and
C). GST-PIASy did not exert any stimulatory activity on BPV
E1 sumoylation, in agreement with the inability of this PIAS
protein to interact with BPV E1. In contrast, GST-PIAS1,
GST-ARIP3, and GST-Miz1 exerted a measurable stimula-
tory activity on BPV E1 sumoylation, increasing the relative
intensity of some of the sumoylation products observed, thus
producing both qualitative and quantitative changes in the
sumoylation patterns (Fig. 5A). Out of the three members of
the PIAS family that stimulated BPV E1 sumoylation, GST-
Miz1 exerted the highest stimulatory activity on BPV E1
sumoylation, leading to a 2.3-fold increase in the apparent
concentration of the most predominant form of sumoylated
BPV E1, while GST-PIAS1 and GST-ARIP3 appeared to
exert lesser but similar stimulatory activities, leading to a 1.5-
fold increase in sumoylated BPV E1, as determined by
phosphordensitometry (Fig. 5C).
Studies by Kotaja et al. (2002) indicated that the integrity
of the RING finger domain is essential for the SUMO-E3
ligase activity exerted by the members of the PIAS family,
as a single amino acid substitution known to disrupt this
domain (the Trp to Ala substitution at position 383 of
ARIP3 discussed above) leads to inactivation of the
sumoylation stimulatory activity of ARIP3. Likewise, the
mutant GST-ARIP3(W383A) exhibited no stimulatory
activity on BPV E1, thus confirming that while the RING
finger domain is not necessary for E1 binding, it is required
for the SUMO ligase activity towards E1. As discussedFig. 6. Miz1 (PIASxh) stimulates the SUMO2 sumoylation of BPV E1 but not of H
were incubated with (+) or without () 1 Ag of SAE1/SAE2, 280 ng of Ubc9, 2 A
GST-Miz1. After incubation, the samples were resolved on an 8% SDS-PAGE ge
patterns of BPV E1 with SUMO1 and GST-SUMO2, respectively. Panels C and
SUMO2, respectively.above, no stimulatory activity on BPV E1 sumoylation was
observed for GST-RanBP2DFG.
Similar experiments performed with HPV11 E1 showed
that the effects mediated by the different PIAS proteins on
HPV11 E1 sumoylation had the same profile as those
observed on BPV E1 sumoylation, although the stimula-
tory effects were less pronounced. For instance, GST-Miz1
exerted the highest stimulatory activity on HPV11 E1
sumoylation but led only to a 1.5-fold increase in HPV11
E1 sumoylation as compared to the unstimulated reactions.
Similarly, no stimulatory activity on HPV11 E1 sumoyla-
tion was observed for PIASy, the RING finger domain
mutant GST-ARIP3(W383A), or GST-RanBP2DFG (Figs.
5B and D).
Miz1 (PIASxb) stimulates the SUMO1 and SUMO2
sumoylation of BPV E1
E3 ligases are thought to enhance the transfer of SUMO
from the E2 conjugating enzyme (Ubc9) to the substrate
while providing specificity to the reaction. To determine if
the stimulatory activity on PV-E1 sumoylation observed for
the PIAS proteins was exclusive for SUMO1 sumoylation,
we performed in vitro sumoylation assays using either BPV
E1 or HPV11 E1 (in vitro translated), SUMO1 or SUMO2,
and different concentrations of GST-Miz1 (the PIAS family
member that exhibited the highest stimulatory activity on
PV-E1 SUMO1 sumoylation). As shown in Fig. 6, GST-
Miz1 stimulated BPV E1 sumoylation with both SUMO1
and SUMO2, reaching a maximum stimulatory activity at
approximately the same concentration for both SUMO
modifiers. However, the apparent yield of sumoylated
BPV E1 was noticeably higher when SUMO1 was used asPV11 E1. In vitro translated and 35S-labeled BPV E1 or HPV11 E1 (1.5 Al)
g of either SUMO1 or GST-SUMO2, and the indicated amounts of purified
l and analyzed by autoradiography. Panels A and B show the sumoylation
D show the sumoylation patterns of HPV11 E1 with SUMO1 and GST-
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modifier for BPV E1 sumoylation. A more dramatic bias
against SUMO2 sumoylation was observed for HPV11 E1.
While GST-Miz1 clearly stimulated the SUMO1 sumoyla-
tion of HPV11 E1 (Fig. 6C), no significant SUMO2
sumoylation was observed for HPV11 E1 even in the
presence of GST-Miz1 (Fig. 6D).
Miz1 stimulates the in vivo sumoylation of BPV E1 and is
expressed in human keratinocytes
The ability of PIAS proteins to stimulate the in vitro
sumoylation of E1 suggested that they might play a similar
role in vivo. To assess this, BPV E1 and Miz1 were
coexpressed by transient transfection in CHO-K1 cells and
the extent of E1 sumoylation was evaluated by immuno-
blotting (Fig. 7). For the initial experiments, an EGFP-E1Fig. 7. Miz1 stimulates the in vivo sumoylation of BPV E1 and is
transcribed in human keratinocytes. CHO-K1 cells were transfected using
the indicated plasmids and amounts, and the transfected cells were collected
30 h posttransfection for preparation of cell extracts as described in
Materials and methods. The cell extracts were either analyzed directly by
immunoblotting using an anti-GFP antibody (panel A) or immunoprecipi-
tated with an anti-HA monoclonal antibody and then analyzed by
immunoblotting using rabbit polyclonal anti-BPV E1 and anti-SUMO
antibodies (panel B). In panels A and B, the arrow indicates the position of
the unsumoylated BPV E1 protein, whereas the arrowheads and the
parenthesis indicate the position of the sumoylated forms. Panel C shows an
agarose gel of the RT-PCR analysis of total RNA purified from HaCaT
human keratinocytes. The position of the 478-bp Miz1 RT-PCR product is
indicated by the arrowhead.construct was utilized as we found that the EGFP fusion
stabilized E1 (unpublished observations) and because it
allowed direct comparisons of transfection efficiencies in
parallel samples. In the absence of Miz1, detection of
sumoylated E1 required exogenous SUMO1 (Fig. 7A, lanes
2 versus 3). Under these conditions, expression of exoge-
nous Miz1 enhanced E1 sumoylation (Fig. 7A, lanes 4 and
5). However, as the overall amount of sumoylated E1
products was low, the experiment was repeated using an
HA-tagged E1 so that E1 proteins could be enriched by
immunoprecipitation with anti-HA prior to immunoblotting
(Fig. 7B). This enrichment procedure greatly facilitated
detection of sumoylated forms of E1. As seen with the direct
immunoblots, exogenous Miz1 stimulated sumoylation
resulting in increased abundance of high molecular weight
forms of E1.
The data presented so far supports the conclusion that
proteins of the PIAS family are likely regulators of PV E1
sumoylation. However, for this observation to be bio-
logically significant, PIAS proteins must be expressed at
the natural site of infection, that is, in keratinocytes. To
verify this, RT-PCR analyses were performed on total RNA
extracted from HaCaT cells, a spontaneously immortalized
keratinocyte cell line that can be induced to undergo a
cellular differentiation resembling that of keratinocytes in
situ. The Miz1 primers utilized were derived from adjacent
exons so a 478-bp PCR product should only be produced
from authentic Miz1 RNA. As shown in Fig. 7C, an RT-
dependent PCR product of the correct size was readily
detected in HaCaT cells, indicating that Miz1 is naturally
transcribed in keratinocytes.Discussion
PV E1 plays a crucial role during the natural history of
papillomavirus infections by initiating episomal replication
of the viral DNA in the host cell via its origin binding and
helicase activity. Previous studies by our group showed that
BPV E1 is modified by sumoylation and that this
posttranslational processing is essential for correct intra-
nuclear localization of BPV E1 (Rangasamy and Wilson,
2000; Rangasamy et al., 2000). As correct intranuclear
localization of BPV E1 is a prerequisite for replication
function, the biological activity of BPV E1 is coupled to its
ability to be sumoylated. Thus, sumoylation can regulate
BPV E1 function, and factors that stimulate or restrict the
sumoylation of BPV E1 may alter the outcome of a
papillomavirus infection.
In this study, we sought to investigate the factors that
regulate the sumoylation of E1. Specifically, we determined
the effect exerted by pseudo-phosphorylation of known
phosphorylated residues in BPV E1 and the ability of two
known SUMO E3 ligases to stimulate BPV E1 and HPV11
E1 sumoylation. While phosphorylation is known to affect
the sumoylation of some other SUMO substrates (Desterro
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2000; Spengler et al., 2002), and the phosphorylation of E1
affects its ability to initiate viral origin replication in vivo
(reviewed in Wilson et al., 2002), none of the pseudo-
phosphorylation BPV E1 mutants showed significant
quantitative or qualitative differences in their sumoylation
profile as compared to the wild-type E1 even when all the
known phosphorylated residues in BPV E1 where pseudo-
phosphorylated simultaneously. Although these experimen-
tal findings do not exclude the possibility that phosphor-
ylation may exert some regulatory role on E1 sumoylation
in vivo (for instance, by limiting the ability of the
sumoylation machinery to interact with E1 while in complex
with a kinase), it suggests that phosphorylation per se does
not alter the ability of E1 to be sumoylated.
As phosphorylation status did not appear to influence E1
sumoylation in vitro, the role of several known SUMO E3
ligases was investigated. Both BPV E1 and HPV11 E1
bound in vitro with all of the members of the PIAS family
tested, except for PIASy, and this interaction was not
dependant on the structural integrity of the RING finger
domain; furthermore, we found that BPV E1 (but not
HPV11 E1) was able to interact with another known SUMO
E3 ligase, RanBP2. Although the BPV E1 binding region on
the PIAS proteins was not mapped, a direct comparison of
the domain organization of PIASy with that of the other
members of the PIAS family used in this study suggests that
the C-terminal end of the PIAS proteins might be critical for
their binding to PV E1. The variation in PIAS family
members is most extensive at the C-terminus with non-E1
binding PIASy being the smallest at 507 amino acids (Fig.
3E). ARIP3 (PIASxa) has an additional 65 amino acids at
its C-terminus compared to PIASy and binds E1 well,
implicating this small region as critical for the interaction.
The effective E1 binding by ARIP3 also suggests that the
longer C-terminal extensions of PIAS1 and Miz1 (PIASxh),
which contain a serine-rich motif, are not essential for E1
interaction.
Next, we tested the ability of the PIAS proteins and
RanBP2 to stimulate PV E1 sumoylation, as a previous
report showed that binding of a given substrate to an E3
ligase does not guarantee that the ligase will enhance the
sumoylation of the substrate (for instance, PIAS3 and
PIASxh interact with the human androgen receptor but do
not enhance its sumoylation; Nishida and Yasuda, 2002).
Because the complex profile of sumoylated forms observed
for BPV E1 and HPV11 E1 was difficult to quantify
accurately in its entirety, the numerical results presented
were based on the intensity of the major sumoylated product
observed in each set of reactions. This simplification
facilitated comparison of all the samples within the same
experiment as wells as the direct comparison of different
experiments. However, because of this simplification, the
quantitative data presented represents an underestimation of
the total sumoylation enhancing effect mediated by the
ligases tested. Using this approach, we found that RanBP2had no effect on sumoylation of either BPV or HPV E1,
although it bound to BPV E1; in contrast, all the PIAS
proteins that exhibited PV E1 binding activity were able to
enhance the in vitro sumoylation of PV E1. In addition to
the quantitative enhancement of sumoylation, there were
also qualitative changes in the pattern of sumoylated
products with some PIAS proteins. While the meaning of
these qualitative changes remains to be determined, we
believe that this combination of quantitative enhancement
and qualitative changes supports the conclusion that PIAS
proteins can act as SUMO ligases for E1 proteins. Miz1 was
the most active on both HPV and BPV E1, with a two- to
threefold stimulation of BPV E1 sumoylation. Additionally,
we also observed that the integrity of the RING finger
domain, while not required for E1 binding, was essential for
the PV E1 sumoylation enhancing activity displayed by the
PIAS proteins. This requirement for an intact RING finger
domain for the SUMO E3 ligase activity displayed by the
PIAS proteins, observed here and in several other reports
(Kahyo et al., 2001; Kotaja et al., 2002; Nakagawa and
Yokosawa, 2002; Nishida and Yasuda, 2002; Schmidt and
Muller, 2002), is attributable to the fact that the RING finger
domain mediates the interaction between PIAS proteins and
Ubc9 (Nishida and Yasuda, 2002).
The differences in the PV E1 sumoylation enhancing
abilities displayed by the different members of the PIAS
family did not correlate with the E1 binding activity as
PIAS1, ARIP3, and Miz1 bound E1 equally well, yet Miz1
was consistently more active in stimulating sumoylation.
Such differences further support a role for the C-terminal
region of the PIAS proteins in their PV E1 sumoylation
enhancing activity, as PIASxa (ARIP3) and PIASxh (Miz1)
differ from each other exclusively at the C-terminal end
(Fig. 3E), yet exhibit substantial differences in their ability
to enhance the sumoylation of BPV E1. Interestingly, while
the SUMO E3 ligase activity exerted by the PIAS proteins
on BPV E1 sumoylation was observed with SUMO1 and
SUMO2, the enhancing effect observed for SUMO2
sumoylation was notably lower. Furthermore, PIAS proteins
failed to enhance the SUMO2 sumoylation of HPV11 E1.
Altogether, the differences observed among the PIAS
proteins in their ability to stimulate PV E1 sumoylation,
and the differences observed in the type of SUMO that is
preferentially used as a modifier during PIAS stimulation,
suggest a degree of specificity in the regulation of PV E1
sumoylation by PIAS proteins.
Sumoylation appears to be predominantly a nuclear
event as most SUMO substrates are nuclear proteins, and
sumoylation of several nuclear proteins has been shown to
require intact nuclear import capacity since mutants
lacking a functional nuclear localization sequence (NLS)
remain unmodified (Kirsh et al., 2002; Rodriguez et al.,
2001). Even though the details of nuclear trafficking by
PV E1 proteins remain mostly uncharacterized, the
prototypical BPV E1 protein resides primarily in the
nucleus and possess a typical NLS (Leng and Wilson,
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E1 proteins will be a nuclear or perinuclear event.
Recently, evidence was presented that sumoylation can
be a biphasic process (Miyauchi et al., 2002) with
addition of SUMO both during nuclear import (utilizing
the nuclear pore-associated RanBP2 E3 ligase activity)
and subsequently within the nucleus via PIAS proteins,
which are exclusively confined to the cell nucleus (Kotaja
et al., 2002; Sachdev et al., 2001; Tussie-Luna et al.,
2002). The lack of PV E1 sumoylation enhancing activity
displayed by RanBP2 in vitro suggests that the binding
observed between BPV E1 and RanBP2 may represent an
interaction established by BPV E1 along its traffic to the
nucleus rather than an interaction established to enhance
E1 sumoylation. In contrast, as PIAS proteins exert a
sumoylation enhancing effect on both BPV and HPV E1
proteins, E1 may traffic to the nucleus in an unsumoy-
lated form and once in the nucleus be sumoylated in
conjunction with nuclear PIAS E3 ligase activity. Intra-
nuclear sumoylation of E1 may be necessary for its
correct localization within the nucleus and/or may
modulate E1 biochemical activities necessary for repli-
cative function.
Consistent with our observations that PIAS proteins
enhanced sumoylation on BPV E1 in vitro, a representa-
tive PIAS protein, Miz1, was also able to stimulate E1
sumoylation in vivo. In addition, we have shown that
Miz1 (Fig. 6C) and the rest of the sumoylation machinery
(A. Deyrieux, unpublished observations) are expressed in
keratinocytes, and that there are changes in host cell
sumoylation patterns during keratinocyte differentiation.
These experiments confirm that sumoylation occurs in the
natural host cells for papillomaviruses and establish that
Miz1 is at least intrinsically capable of functionally
interacting with the E1 sumoylation complex in vivo.
However, whether or not Miz1 is the primary endogenous
SUMO ligase for E1 proteins is still uncertain. Other
PIAS proteins, or additional unidentified SUMO ligases,
may exert a much more profound enhancing effect on PV
E1 sumoylation in vivo. Additionally, the cross-talk that is
likely to occur in vivo between the different posttransla-
tional modifications affecting PV E1, including phosphor-
ylation (Cueille et al., 1998; Lentz, 2002; McShan and
Wilson, 1997; Zanardi et al., 1997) and ubiquitination
(Malcles et al., 2002), may modulate the function of
SUMO ligases in PV E1 sumoylation. Extensive addi-
tional experimentation will be required to determine if
endogenous Miz1, other members of the PIAS protein
family, or another SUMO ligase altogether functions as
the actual E3 enzyme for sumoylation of papillomaviral
E1 proteins. Nonetheless, it is tempting to speculate that
E1 function might be regulated by alterations in sumoy-
lation activity or specificity as the virus-infected cells
differentiate.
Lastly, the profile of sumoylated forms observed for
BPV E1 in this study differs from the one previouslyreported (Rangasamy et al., 2000). In the former studies, a
single, predominant sumoylated form of BPV E1 was
observed in vitro, while in the current studies a more
complex array of sumoylated products was detected even in
the absence of PIAS proteins. The profile obtained in the
present study suggests two possible scenarios: (1) BPV E1
may contain other potential sumoylation sites that are being
used under the sumoylation assay conditions used in this
study, leading to its sumoylation at multiple sites, or (2) the
SUMO1 added at the single previously mapped sumoylation
site (Lys 514) in BPV E1 may be undergoing polysumoy-
lation (SUMO1 chain formation). SUMO1 was initially
considered unable to undergo chain formation due to the
lack of a lysine displaying the consensus sumoylation
sequence and no experimental data indicative of SUMO1
polysumoylation (Tatham et al., 2001). However, later
reports have given strong support to the idea that SUMO1
can form chains in vitro (Netzer et al., 2002; Pichler et al.,
2002), and we have also observed this for sumoylation of
RanBP2 in vitro (unpublished observations). Although at
present we cannot distinguish between these scenarios, we
consider that an important contributing factor to the
differences observed is the use of E. coli-expressed, purified
SAE1/2 in this study versus the use of partially enriched
SAE1/2 from mammalian cell extracts in our previous
reports. Hence, a higher enzymatic-specific activity com-
bined with a decrease in the total pool of possible
sumoylation substrates could result in either of the scenarios
described above. Alternatively, an unknown E3 ligase or
other factor that limits the spectrum of SUMO-modifiable
lysine residues in BPV E1 (thus increasing the specificity of
sumoylation) may have been present in the cell extracts
previously used. Studies are in progress to further under-
stand the extent and regulation of E1 sumoylation by
SUMO ligases in vivo. Meanwhile, regardless of the
authentic in vivo SUMO ligase for E1 modification, the
ability of PIAS proteins to enhance E1 sumoylation should
facilitate production of increased amounts of sumoylated E1
for future biochemical analysis.Materials and methods
Expression plasmids, protein expression, and purification
The PIAS1 expression plasmid was provided by Dr.
Hideyo Yasuda (Kahyo et al., 2001). The pGEX4T3-ARIP3,
pGEX4T3-ARIP3(W383A), and pGEX5X1-Miz1 plasmids
for the expression of PIASxa (ARIP3), the RING finger
domain mutant of PIASxa (ARIP3[W383A]), and PIASxh
(Miz1), respectively (Kotaja et al., 2000, 2002), were
provided by Dr. Jorma J. Palvimo. The pGEX2T-mPIASy
plasmid for the expression of PIASy (Sachdev et al., 2001)
was provided by Dr. Rudolf Grosschedl. The pGEX3X
plasmid for the expression of RanBP2DFG (Pichler et al.,
2002) was provided by Dr. Frauke Melchior. All of the
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proteins and purified by affinity chromatography on
glutathione-sepharose 4B beads (Amersham Pharmacia
Biotech, Piscataway, NJ) using a modified version of a
previously described method (Gonzalez et al., 2000).
Briefly, E. coli BL21 bacteria containing the appropriate
plasmid were grown in 250 ml of liquid media at 37 8C to
an optical density of 1.0 (wavelength: 600 nm), incubated
on ice for 4 min, induced with 0.2 mM isopropyl-thio-h-d-
galactoside, and incubated at room temperature for 4 h. The
cells were collected by centrifugation, resuspended in 1
PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4, pH 7.3) containing 5 mM DTT and 1/100
volume of protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO), treated with lysozyme at a final concentration
of 0.1 mg/ml, lysed by two passages through a prechilled
French press cell at 16,000 lb/in2, and sonicated briefly. The
resulting extract was clarified at 12,000  g for 15 min, and
the supernatant was incubated with the glutathione-sephar-
ose 4B beads for 2 h at 4 8C. The beads were washed with
20 bead volumes of 1 PBS, 10 bead volumes of 1 PBS
containing 750 mM NaCl, and another 10 bead volumes of
1 PBS, and bound proteins were eluted with 20 mM
reduced glutathione, 100 mM Tris pH 8.0, 120 mM NaCl.
The eluted proteins were dialyzed overnight against 1
TBS (50 mM Tris pH 7.4, 150 mM NaCl) supplemented
with 10% glycerol, aliquoted into 20–50 Al samples, and
stored at 70 8C. The purified proteins were assessed by
SDS-PAGE followed by Coomassie blue staining or West-
ern blotting performed using goat anti-GST antibodies
(Amersham Pharmacia Biotech) and peroxidase-conjugated
rabbit anti-goat IgG secondary antibodies (SIGMA-
Aldrich), with signal detection by chemiluminescence using
the Western Lightning reagent (PerkinElmer Life Sciences,
Inc., Boston, MA). Protein concentrations were determined
by a Bradford assay (Bradford, 1976). The GST-SAE1/
SAE2 expression plasmid was provided by Dr. Ronald T.
Hay (Tatham et al., 2001), and SAE1/SAE2 were coex-
pressed and copurified as above except that the proteins
were eluted off the beads by Thrombin digestion. Ubc9 was
expressed using a previously described pGEX-5X-1-based
expression plasmid (Rangasamy and Wilson, 2000) and
purified as above with elution by Factor Xa digestion. GST-
SUMO2 was expressed from a pGEX expression plasmid
provided by Dr. Hisato Saitoh and purified as above. Human
SUMO1 was cloned into plasmid pRSET (Invitrogen Corp.,
Carlsbad, CA) from a plasmid provided by Dr. Joana
Desterro; SUMO1 was expressed and purified in E. coli
BL21(DE3) bacteria as above, with the modifications
indicated below. First, the cells were resuspended in a 1
PBS containing 500 mM NaCl and 5 mM imidazole;
second, an Ni2+-NTA-Agarose resin (QIAGEN Inc., Valen-
cia, CA) was used for the purification; and third, the washes
and the elution were performed by using a 1 PBS buffer
containing increasing concentrations of imidazole (50 mM
for the final wash, 500 mM for the elution).Plasmids and procedures for in vitro protein expression
pRSET constructs containing either full-length or trun-
cated forms of BPV E1 were described in a previous study
(Rangasamy and Wilson, 2000). Targeted mutagenesis for
the introduction of Asp substitutions for known phosphory-
lated Thr and Ser residues (pseudo-phosphorylation muta-
tions) in the pRSET BPV E1 construct were performed
using the QuikChange XL Site-Directed mutagenesis kit
(Stratagene, La Jolla, CA), as indicated by the manufacturer.
Plasmid pCR3-HPV11-E1, containing the full-length
HPV11 E1 (Titolo et al., 1999), was provided by Dr.
Jacques Archambault. Plasmid HA-Sp100A/pSG5, coding
for an HA-tagged Sp100 (Seeler et al., 1998), was provided
by Dr. Jacob S. Seeler and was used as a control to verify
the E3 SUMO ligase activity of the purified GST-
RanBP2DFG. All the above constructs were used in coupled
in vitro transcription and translation reactions to produce
35S-labeled proteins. Briefly, approximately 1–2 Ag of
plasmid DNA were mixed with 32 ACi of Redivue l-
(35S)-methionine (Amersham Pharmacia Biotech) and 25 Al
of the TNT T7 Quick Coupled transcription/translation
system (Promega Corp., Madison, WI), then incubated at
30 8C for 90 min. After incubation, the samples were flash-
frozen at 70 8C or used directly in pulldown experiments
or in vitro sumoylation assays.
Pulldown experiments
Purified GST fusion proteins (2, 6, or 12 Ag) were
incubated with 20 Al of glutathione-Sepharose 4B beads and
3 Al of the 35S-labeled in vitro translated protein in 500 Al
reactions containing 1 TBS buffer supplemented with 1%
Tween 20, 5 mM MgCl2 (1 TTBS-MgCl2), and 5 mg/ml
BSA. The incubations were performed at 4 8C in a circular
rotator for 3 h. After incubation, the samples were
centrifuged at 5,000  g for 30 s, the supernatant was
discarded, and the beads were resuspended in 1 ml of ice-
cold 1 TTBS-MgCl2. The washes were repeated three
additional times, and after the final wash the supernatant
was discarded and the beads were resuspended in 25 Al of
4 SDS-PAGE sample buffer, incubated at 95 8C for 3 min,
and the resulting mixture was loaded on an SDS-PAGE gel.
The proteins in the gel were blotted onto Immobilon
(Millipore Corp., Bedford, MA), and the membrane was
developed by autoradiography. Quantitative analysis of the
resulting profile of 35S-labeled proteins on the membrane
was performed by phosphordensitometry analysis using a
Storm 860 laser scanning system and ImageQuant analysis
software (both from Molecular Dynamics Inc., Amersham
Pharmacia Biotech).
In vitro sumoylation assays
In vitro sumoylation assays were carried out mostly as
described (Rangasamy et al., 2000), except that the partially
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from NIH 3T3 cells previously used was replaced by a
bacterially expressed affinity purified SAE1/SAE2. Briefly,
2 Al of 35S-labeled in vitro translated BPV E1 or HPV11 E1
were incubated with or without 1 Ag of SAE1/SAE2, 280 ng
of Ubc9, 1.5 Ag of SUMO1 or GST-SUMO2, and the
indicated amounts of the purified E3 SUMO ligases. All the
in vitro sumoylation reactions were performed in a buffer
containing 50 mM Tris pH 8.0, 5 mM MgCl2, 5 mM ATP,
and 0.5 mM DTT, in a final volume of 25 Al, at 30 8C for 90
min. The reactions were stopped by adding 9 Al of 4 SDS-
PAGE sample buffer. Then, the samples were incubated at
958C for 3 min, loaded on an SDS-PAGE gel, and processed
and quantified as described for the pulldown experiments.
Cell culture, transfections, immunoprecipitations, RNA
purification, and RT-PCR
CHO-K1 and HaCaT cells were grown in 10% FBS-
supplemented Ham’s F12 medium or DMEM, respectively,
and were maintained at 37 8C and 5% CO2 in a humidified
incubator. CHO-K1 cell transfections were performed using
Lipofectamine 2000 (Invitrogen) according to the supplier’s
recommendations. Plasmids pcDNA3/HA-SUMO1,
pcDNA3.1/SUMO1, pcDNA3.1/HA-E1, and pEGFP-E1
have been described previously (Rangasamy and Wilson,
2000; Rangasamy et al., 2000). Plasmid pFLAG-Miz1 was
kindly provided by Dr. Jorma J. Palvimo. Immunoprecipi-
tations were performed as previously reported (Rangasamy
and Wilson, 2000). For RNA isolation, HaCaT cells were
harvested by trypsinization and RNA was extracted using
the RNAqueous-Midi Kit (Ambion, Inc. Austin, TX). The
total RNA obtained was stored at 80 8C.
For the RT-PCR amplification of Miz1 (PIASxh), we
used the primers 5VATGGTGGCTCATCACCTGTAGAAC
3V and 5VGCATAGCCAGGCAAAGGAAATAGC 3V, which
target sequences located on exon 2 and overlapping exons
5–6 junction, respectively. These primers were designed
based on the predicted Miz1 transcripts from accession no.
MN_004671 in the NCBI database. The above primers
produce an amplicon of 478 bp. The one-step RT-PCR was
performed on 7.5 Ag of total HaCaT RNA in 25 Al
reactions using MMLV reverse transcriptase (Invitrogen)
and Platinum DNA Taq polymerase (Invitrogen) in the
presence of RNaseOUT Recombinant Ribonuclease Inhib-
itor (Invitrogen). For every test reaction, a negative control
without reverse transcriptase was performed. The final PCR
product was analyzed by gel electrophoresis on a 2.2%
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